These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34810212)

  • 1. Deregulation of AKT-mTOR Signaling Contributes to Chemoradiation Resistance in Lung Squamous Cell Carcinoma.
    Shen C; Shyu DL; Xu M; Yang L; Webb A; Duan W; Williams TM
    Mol Cancer Res; 2022 Mar; 20(3):425-433. PubMed ID: 34810212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma.
    Castellano GM; Zeeshan S; Garbuzenko OB; Sabaawy HE; Malhotra J; Minko T; Pine SR
    Mol Cancer Ther; 2022 Sep; 21(9):1381-1392. PubMed ID: 35732569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The NRF2 antagonist ML385 inhibits PI3K-mTOR signaling and growth of lung squamous cell carcinoma cells.
    Ji L; Moghal N; Zou X; Fang Y; Hu S; Wang Y; Tsao MS
    Cancer Med; 2023 Mar; 12(5):5688-5702. PubMed ID: 36305267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation.
    Quintanal-Villalonga A; Taniguchi H; Zhan YA; Hasan MM; Chavan SS; Meng F; Uddin F; Allaj V; Manoj P; Shah NS; Chan JM; Ciampricotti M; Chow A; Offin M; Ray-Kirton J; Egger JD; Bhanot UK; Linkov I; Asher M; Roehrl MH; Ventura K; Qiu J; de Stanchina E; Chang JC; Rekhtman N; Houck-Loomis B; Koche RP; Yu HA; Sen T; Rudin CM
    J Hematol Oncol; 2021 Oct; 14(1):170. PubMed ID: 34656143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma.
    Xu W; Wei Y; Li Y; Yin Y; Yuan W; Yang Y; Zhao W; Wu J
    Oncol Rep; 2017 Sep; 38(3):1815-1821. PubMed ID: 28737828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capsaicin reverses cisplatin resistance in tongue squamous cell carcinoma by inhibiting the Warburg effect and facilitating mitochondrial-dependent apoptosis via the AMPK/AKT/mTOR axis.
    Liu X; Li Z; Zhao Q; Zhou X; Wang Y; Zhao G; Guo X
    Cell Biol Int; 2024 Aug; 48(8):1097-1110. PubMed ID: 38706122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of autophagy by andrographolide resensitizes cisplatin-resistant non-small cell lung carcinoma cells via activation of the Akt/mTOR pathway.
    Mi S; Xiang G; Yuwen D; Gao J; Guo W; Wu X; Wu X; Sun Y; Su Y; Shen Y; Xu Q
    Toxicol Appl Pharmacol; 2016 Nov; 310():78-86. PubMed ID: 27639426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BEZ235 reduction of cisplatin resistance on wild-type EGFR non-small cell lung cancer cells.
    Wang R; Li A; Liu J; Fang M; Zhu Y; Huang J; Liu Y; Huo L; You Q
    J Chemother; 2023 Apr; 35(2):95-103. PubMed ID: 35238281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA-PK-Mediated Cytoplasmic DNA Sensing Stimulates Glycolysis to Promote Lung Squamous Cell Carcinoma Malignancy and Chemoresistance.
    Wang H; Zhang Y; Tian Y; Yang W; Wang Y; Hou H; Pan H; Pei S; Zhu H; Gu Z; Zhang Y; Dai D; Chen W; Zheng M; Luo Q; Xiao Y; Huang J
    Cancer Res; 2024 Mar; 84(5):688-702. PubMed ID: 38199791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
    Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
    Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
    Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
    Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
    Zheng R; Jiang H; Li J; Liu X; Xu H
    Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
    Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
    Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of vitamin D on malignant behavior of non-small cell lung cancer cells.
    Songyang Y; Song T; Shi Z; Li W; Yang S; Li D
    Gene; 2021 Feb; 768():145309. PubMed ID: 33197518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T; Cui L; Wang H; Wang H; Han N
    J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin enhances cisplatin sensitivity of resistant non-small cell lung carcinoma stem-like cells by targeting mTOR-Akt axis to repress migration.
    Khan P; Bhattacharya A; Sengupta D; Banerjee S; Adhikary A; Das T
    Sci Rep; 2019 Nov; 9(1):16913. PubMed ID: 31729456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition.
    Feng FF; Cheng P; Sun C; Wang H; Wang W
    Chin J Nat Med; 2019 Oct; 17(10):768-777. PubMed ID: 31703757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of lysine (K)-specific demethylase 2B KDM2B inhibits glycolysis and induces autophagy in lung squamous cell carcinoma cells by regulating the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway.
    Xie Z; Li H; Zang J
    Bioengineered; 2021 Dec; 12(2):12227-12235. PubMed ID: 34783291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.
    Shin DH; Min HY; El-Naggar AK; Lippman SM; Glisson B; Lee HY
    Mol Cancer Ther; 2011 Dec; 10(12):2437-48. PubMed ID: 21980128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.